BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Robert S. Cowles, III, M.D. Joins Urodyne, Inc. and Hyperdyne, Inc., Two Subsidiaries Trimedyne, Inc. (TMED) Plans to Organize, as Co-Chairman and Medical Director


12/20/2012 8:44:00 AM

LAKE FOREST, CA--(Marketwire - December 20, 2012) - TRIMEDYNE, INC. ("Trimedyne") (OTCBB: TMED) today announced that Robert S. Cowles, III, M.D. has agreed to serve as Co-Chairman with Dr. Marvin P. Loeb of the Boards of Directors and as Medical Director of Urodyne, Inc. ("Urodyne") and Hyperdyne, Inc. ("Hyperdyne"), two subsidiaries Trimedyne plans to organize. (See Trimedyne's Press Release of November 28, 2012).

Dr. Cowles will be the Chief Investigator of, and subject to their being funded, will direct the randomized, controlled clinical trials to be conducted by Urodyne and Hyperdyne throughout the world. He will also select the medical centers to participate in these clinical trials in North and South America and will train the Urologists of these medical centers on the use of the new lasers and new, disposable fiber-optic devices to be tested in these clinical trials.

Subject to the receipt of funding, Urodyne plans to conduct three (3), 300 patient, randomized, controlled clinical trials of its new lasers and new, disposable fiber-optic devices in the faster and safer treatment of Benign Prostatic Hyperplasia or "BPH," commonly referred to as an "Enlarged Prostate," as well as in the treatment of urinary incontinence and fecal incontinence. These three conditions affect more than 50 million Americans and cost Medicare, insurers and their families an estimated $60 billion dollars each year in the United States.

Likewise, Hyperdyne plans to conduct two (2), 300 patient, randomized, controlled clinical trials of its new lasers and new, disposable fiber-optic devices. One clinical trial will be in the Endoscopic or Laparoscopic treatment of Hypertension (high blood pressure) not controllable by drugs. The other clinical trial will be in the Percutaneous (intra-renal artery) treatment of uncontrolled Hypertension. Uncontrolled Hypertension affects an estimated 26 million Americans and costs Medicare, insurers and society an estimated $26 billion each year in the United States. Uncontrolled Hypertension affects an estimated $400 million people outside the U.S. and costs an estimated $186 billion each year in countries outside the U.S.

Trimedyne manufactures proprietary Holmium lasers and patented and patent pending fiber optic laser devices to treat a variety of medical conditions in minimally invasive, procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial, SEC Reports and other information, please visit Trimedyne's website, http://www.trimedyne.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "believe," "expect," "may," "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC Reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in the statements in such Reports, which Trimedyne has no obligation to update.


CONTACT:
Jeffrey Rudner
(949) 951-3800, Ext. 285
jrudner@trimedyne.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES